Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761436 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Safety and Efficacy of Spheramine
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00761436: Clinical Trial Phase 2 study, sponsored by Bayer.
NCT00761436 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00761436, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease
Interventions
- BIOLOGICAL Spheramine (BAY86-5280)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2000-02-29 |
| Est. Completion | 2012-05-14 |
| Phase | Phase 2 |
Why NCT00761436 stopped before completion
NCT00761436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Spheramine (BAY86-5280) is the first listed.
NCT00761436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00761436 about?
NCT00761436 is a clinical study titled "Pilot Study of Safety and Efficacy of Spheramine". Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease
What is the current status of trial NCT00761436?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2000-02-29. Estimated completion is 2012-05-14.
What interventions are being tested in trial NCT00761436?
The interventions under investigation include: Spheramine (BAY86-5280) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00761436?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00761436's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI